Previous 10 | Next 10 |
Arena Pharmaceuticals (NASDAQ: ARNA ) is scheduled to announce Q2 earnings results on Wednesday, August 5th, after market close. The consensus EPS Estimate is -$2.00 (-61.3% Y/Y) and the consensus Revenue Estimate is $1.47M (+44.1% Y/Y). Over the last 2 years, ARNA has beaten EPS esti...
SAN DIEGO , July 29, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2020 financial results and provide a corporate update on Wednesday, August 5, 2020 , after the close of the U.S. financial markets. The Company will host a question and ...
Will These Pot Stocks Survive The Cannabis Industry In the Long Term As we search the cannabis industry for marijuana stocks to watch, finding the right ones can be difficult. Which pot stock has all the right financials and future plans on tap? Which pot stock will be able to survive with...
With so many companies struggling in the cannabis market , it's easy to predict doom and gloom for the whole industry, but that's far from the case. It's just an emerging market with a ridiculous upside, and some companies are bound to struggle. It may be inevitable that many in the sector won...
SAN DIEGO , June 15, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Dr. Katharine Knobil to the Company's Board of Directors. Dr. Knobil brings more than 20 years of leadership and expertise across a range of areas including global c...
SAN DIEGO , June 8, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced changes to its research and development leadership team. Effective June 9, 2020 , Dr. Preston Klassen will be leaving the Company to pursue an opportunity as Chief Executive Officer of...
Here are the top stocks making major technical noise this week from Harry Boxer . Several stocks made important moves on significant volume, signaling that a greater breakout may be on the horizon. These include: Arena Pharmaceuticals, Inc. ( ARNA ) broke out, and I put a swing trade ...
Shares of Arena Pharmaceuticals (NASDAQ: ARNA) are up 13% at 2: 13 p.m. EDT because its rival, Bristol Myers Squibb (NYSE: BMY) , reported positive data on Zeposia in patients with ulcerative colitis. Zeposia targets the sphingosine-1-phosphate (S1P) receptor, just like A...
Arena Pharmaceuticals (NASDAQ: ARNA ) has priced its public offering of 5.5M common shares at $50.00/share, for expected gross proceeds of $275M. More news on: Arena Pharmaceuticals, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
SAN DIEGO , May 28, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $50.00 per share. All of the shares are being sold by Arena. The gr...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...